Comparative pharmacokinetics of new quinolones.
The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration. However, each quinolone derivative (ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin) possesses individual pharmacokinetic characteristics, which should be considered in the treatment of patients, especially when liver and/or renal dysfunction exists.
D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D015365:Enoxacin; D006801:Humans; D009287:Naphthyridines / Q000493:pharmacokinetics; D009643:Norfloxacin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D015242:Ofloxacin; D010078:Oxazines / Q000493:pharmacokinetics; D015366:Pefloxacin; D011804:Quinolines / Q000493:pharmacokinetics*
D000890:Anti-Infective Agents; D009287:Naphthyridines; D010078:Oxazines; D011804:Quinolines; D015366:Pefloxacin; D015365:Enoxacin; D015242:Ofloxacin; D009643:Norfloxacin